Cédric van Marcke

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Collaborators (4)

Pierre Roger

Université libre de Bruxelles

Sandra Schmitz

Marc Van den Eynde

Associate Professor

Université catholique de Louvain

Åslaug Helland

University of Oslo

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Cédric van Marcke

Research Interests

Explore related searches

Contact this professor

Articles (12)

Collaborators (4)

Pierre Roger

Sandra Schmitz

Marc Van den Eynde

Åslaug Helland

Make your next move.

Cédric van Marcke

Research Interests

Explore related searches

Contact this professor

Articles (12)

Tumor-Informed ctDNA Assay to Predict Outcome in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with PD-1 Inhibitor

The gut microbiome and cancer: from tumorigenesis to therapy

A federated learning system for precision oncology in Europe: DigiONE

Evaluation of trophoblast cell surface antigen-2 (TROP2) protein expression in chemotherapy-resistant and metastatic breast carcinomas

Acquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma

Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.

Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.

Acute leukoencephalopathy and thyroiditis induced by capecitabine

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants.

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck.

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact

Collaborators (4)

Pierre Roger

Sandra Schmitz

Marc Van den Eynde

Åslaug Helland

Make your next move.